Form 4: Assembly Biosciences Executive Granted Stock Options

William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, received 20,000 stock options on March 29, 2024, according to a Form 4 filing.

Summary

• William E. Delaney IV, the Chief Scientific Officer of Assembly Biosciences, Inc., was granted 20,000 stock options on March 29, 2024.
• The options have an exercise price of $13.30.
• The options vest over four years, with 25% vesting on March 29, 2025, and the remaining 75% vesting in 36 monthly installments, becoming fully vested on March 29, 2028.
• The options expire on March 29, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is moderately positive as it indicates continued investment in key personnel.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders, incentivizing him to drive company success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with those of shareholders. This is a standard method for retaining talent and driving innovation within the company.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally determined based on industry benchmarks and the executive's role and performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to drive company growth and innovation.
• Employees may see this as a positive sign of investment in leadership and the company's future.

Key Dates